Abstract: In one aspect, the disclosure relates to relates to compositions, devices, and processes for drug delivery to an eye. The disclosed drug delivery compositions comprise a particle having a core component comprising a first polymer and a therapeutic agent, and a shell layer surrounding the core component comprising a second polymer. In a further aspect, the present disclosure relates to methods of treating an ophthalmological disease or disorder. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Type:
Grant
Filed:
April 11, 2019
Date of Patent:
May 30, 2023
Assignee:
Ohio State Innovation Foundation
Inventors:
Pengfei Jiang, Katelyn Elizabeth Reilly, Matthew Ohr
Abstract: A method of preparing a nanoparticle pharmaceutical delivery system. A nanoparticle pharmaceutical delivery system. A method of preparing a targeted nanoparticle pharmaceutical delivery system. A targeted nanoparticle pharmaceutical delivery system.
Abstract: Disclosed are an oxazine compound and an application thereof. The oxazine compound has a structure of a general formula F. The oxazine compound described in the disclosure is a photo/acoustic dynamic active organic molecule with near-infrared absorption-emission function as well as photosensitivity and acoustic sensitivity. Maximum absorption and emission wavelengths of the compound are both greater than 660 nanometers, and a triplet-state conversion rate of the compound is high; and under illumination or ultrasound, the compound can produce reactive oxygen species with high efficiency, which has a good killing effect on cancer cells and cancer tissues, and almost has no toxic or side effects on normal tissues while achieving photo/acoustic dynamic therapy on tumors.
Type:
Grant
Filed:
April 22, 2019
Date of Patent:
May 2, 2023
Assignees:
DALIAN UNIVERSITY OF TECHNOLOGY, DALIAN CHROMAS BIOSCIENCE CO., LTD
Abstract: A method of preparing iron oxide nanoparticles using an herbal mixture comprising Capparis spinosa, Cichorium intybus, Solanum nigrum, Cassia occidentalis, Terminalia arjuna, Achillea millefolium, and Tamarix gallica. The method produces crystalline ?-Fe2O3 nanoparticles which are superparamagnetic. The iron oxide nanoparticles are used in a method of killing or inhibiting the growth of a bacteria and/or fungus, particularly in the form of a biofilm. The nanoparticles are also used in a method of treating colon cancer.
Abstract: Drift reduction adjuvant composition and agricultural sprays containing such agricultural compositions contain water, a Newtonian responding polymer such as guar gum, an emulsifier such as a polyoxyethylene sorbitan emulsifier, and an oil. When the agricultural spray containing the drift reduction adjuvant composition and a pesticide is delivered from an agricultural nozzle, it produces fewer droplets less than 150 ?m in diameter and either reduces, maintains or increases (e.g., by up to 30 percentage points) the number of ultra-coarse droplets above 622 ?m in diameter compared to an agricultural spray of the pesticide without the drift reduction adjuvant composition sprayed under the same conditions.
Abstract: The present invention relates to a combination of a flexible container of the type with a brush and a tube enclosing a homogeneous suspension composed of an aqueous phase and of an oily phase which has at least one active principle, characterized in that the container has an applicator consisting of friction members suitable for applying said suspension at the outlet of an orifice onto a zone of the body of a subject to be treated, said suspension having a suitable viscosity allowing it to be distributed homogeneously via said members of said applicator.
Abstract: Use of a TNFR1-FADD-caspase8-caspase3 pathway inhibitor in preparation of a medicament for treating an immune system related disease caused by autoinducer, a method for screening a medicament for treating an immune system related disease caused by autoinducer and a method for treating an immune system related disease.
Abstract: Improved RNA interference (RNAi) efficiency in insects is disclosed herein. In particular, certain embodiments of the presently-disclosed subject matter relate to use of nanoformulations of double-stranded RNA (dsRNA) to limit nuclease degradation of the dsRNA, and enhance cellular update and intracellular transport to improve delivery of the dsRNA to enhance RNAi in insects.
Type:
Grant
Filed:
April 17, 2020
Date of Patent:
February 7, 2023
Assignee:
University of Kentucky Research Foundation
Abstract: Described herein are peptides, compositions, and methods for diagnosing, detecting, imaging, monitoring, preventing, treating, or ameliorating diseases or disorders including cancer, inflammatory disorder, and autoimmune disease.
Type:
Grant
Filed:
September 28, 2018
Date of Patent:
February 7, 2023
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Inventors:
Tambet Teesalu, Pablo Scodeller, Erkki Ruoslahti
Abstract: The present invention is directed to methods for inhibiting growth of bacteria and to nanometer scale surfaces having antibacterial properties.
Abstract: In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.
Abstract: The present invention provides 18F-labeled amino acids or derivatives thereof having formula (I) and methods of making same, which can be suitable for PET imaging:
Type:
Grant
Filed:
August 23, 2017
Date of Patent:
December 27, 2022
Assignee:
Simon Fraser University
Inventors:
Paul Schaffer, Hua Yang, Robert Britton, Matthew Nodwell, Zheliang Yuan
Abstract: Embodiments of the invention include drug delivery coatings and devices including the same. In an embodiment, the invention includes a drug delivery coating including a polymeric layer. The polymeric layer can include a hydrophilic outer surface. The coating can also include a matrix contacting the hydrophilic outer surface. The matrix can include a particulate hydrophobic therapeutic agent and a cationic agent. The polymeric layer can further include a hydrophilic polymer having pendent photoreactive groups and a photo-crosslinker including two aryl ketone functionalities. Other embodiments are also included herein.
Type:
Grant
Filed:
April 13, 2020
Date of Patent:
December 20, 2022
Assignee:
Surmodics, Inc.
Inventors:
Joram Slager, Toni M. Heyer, David E. Babcock
Abstract: There is provided a method of preparing silica nanocapsules, the method comprising mixing a surfactant with water at a temperature that is above the gel-to-liquid transition temperature of the surfactant to form a mixture, passing the mixture one or more times through at least one pore to obtain a dispersion of vesicles, and adding a silica precursor to the dispersion of vesicles to form silica nanocapsules. Also provided is a silica nanocapsule formed from a vesicle template, and a method of delivering one or more types of molecules to a subject. In a specific embodiment, hollow silica nanocapsules having substantially lens-shaped are synthesized by employing dimethyldioctadecylammonium bromide (DODAB) or dioctadecyldimethyl ammonium chloride (DODAC) as the vesicle template and tetraethyl orthosilicate (TEOS) as the silica precursor.
Type:
Grant
Filed:
March 28, 2018
Date of Patent:
December 20, 2022
Assignee:
Agency for Science, Technology and Research
Inventors:
Eun Ju Park, Alexander M. Van Herk, Praveen Thoniyot
Abstract: The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors. The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in methods of treating disease and for imaging of disease.
Type:
Grant
Filed:
August 21, 2018
Date of Patent:
December 13, 2022
Assignee:
Purdue Research Foundation
Inventors:
Philip S. Low, Isaac J. Marks, Spencer Gardeen, Sumith A. Kularatne
Abstract: The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ?ijk equal to or above 200, and an insulator material with a dielectric constant ?ijk equal to or below 100.
Abstract: Disclosed are methods useful for the topical therapeutic treatment of cervical intraepithelial neoplasia (CIN) and/or cervical cancer using compositions containing nanoparticles of paclitaxel or other taxanes.
Abstract: The invention generally relates to compositions of hypochlorous acid (HOCl) and methods of manufacture thereof. In certain aspects, the invention provides air-free compositions of HOCl. In other aspects, the invention provides methods of making HOCl that involve mixing together in water in an air-free environment, a compound that generates a proton (H+) in water and a compound that generates a hypochlorite anion (OCl?) in water to thereby produce air-free hypochlorous acid.
Abstract: The present invention provides a hybrid biocompatible carrier (hybridosome) which comprises structural and bioactive elements originating from at least one biocompatible delivery module (BDM) and at least one engineered drug encapsulation module (EDEM) comprising at least one tunable fusogenic moiety. The invention further provides pharmaceutical compositions comprising said hybridosomes, processes for their manufacture, as well as pharmaceutical uses and pharmaceutical methods based thereon.